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 1 
Abstract 
 
Despite improvements in implants and surgical techniques, osteoporotic fractures remain 
challenging to treat. Among other major risk factors, decreased expression of morphogenetic 
proteins has been identified for impaired fracture healing in osteoporosis. Bone grafts or bone 
graft substitutes are often used for stabilizing the implant and for providing a scaffold for 
ingrowth of new bone. Both synthetic and naturally occurring biomaterials are available. 
Products generally contain hydroxyapatite, tricalcium phosphate, dicalcium phosphate, 
calcium phosphate cement, calcium sulfate (plaster of Paris), or combinations thereof. 
Products have been used for the treatment of osteoporotic fractures of the proximal humerus, 
distal radius, vertebra, hip, and tibia plateau. Although there is generally consensus that screw 
augmentation increased the biomechanical properties and implant stability, the results of 
using these products for void filling are not unequivocal. In osteoporotic patients, BMPs have 
the potential impact to improve fracture healing by augmenting the impaired molecular and 
cellular mechanisms. However, the clinical evidence on the use of BMPs in patients with 
osteoporotic fractures is poor as there are no published clinical trials, case series or case 
studies. Even pre-clinical literature on in vitro and in vivo data is weak as most articles focus 
on the beneficial role for BMPs for restoration of the underlying pathophysiological factors of 
osteoporosis but do not look at the specific effects on osteoporotic fracture healing. Limited 
data on animal experiments suggest stimulation of fracture healing in ovariectomized rats by 
the use of BMPs. In conclusion, there is only limited data on the clinical relevance and 
optimal indications for the use of bone graft substitute materials and BMPs on the treatment 
of osteoporotic fractures despite the clinical benefits of these materials in other clinical 
indications. Given the general compromised outcome in osteoporotic fractures and limited 
alternatives for enhancement of fracture healing, clinicians and researchers should focus on 
this important topic and provide more data in this field in order to enable a sound clinical use 
of these materials in osteoporotic fractures.  
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Introduction 
Despite improvements in the treatment of osteoporosis, osteoporotic fractures remain 
challenging to treat. Osteoporotic fractures have an impaired ability to heal (1, 2), and often 
require more time to heal (3-6). Since osteoporotic bone is less likely to heal on its own and 
the degree of comminution is generally high, patients often require surgery to repair the 
fracture. Poor bone quality, however, may complicate implant fixation. Modern angle-stable 
plate-screw systems and minimally invasive operative techniques have improved the stability 
of fixation in osteoporotic bone, but success is still not guaranteed. Due to the high porosity 
and low mechanical strength of osteoporotic cancellous bone, implants are often augmented 
with bone void fillers in order to improve outcome. Furthermore, decreased expression of 
bone morphogenetic proteins (BMPs) in osteoporosis combined with the essential general role 
of BMPs in fracture healing made BMPs attractive for improvement of impaired molecular 
and cellular mechanisms in osteoporotic fracture patients (7).  
Bone grafts can be used to stabilize the implants and provide a scaffold for ingrowth of 
new bone. BMPS have the potential of de novo new bone formation due to their 
osteoinductive capabilities (8).   
So, these materials are suitable as bone grafts fill voids, provide support, and may 
enhance the biological repair of the fracture or the fracture defect. This paper is aimed at 
providing an overview of available evidence for the use of bone graft substitutes and BMPs 
for the treatment of osteoporotic fractures. 
 
Bone graft substitute materials 
The limitations of autografts and allografts led to the development of bone graft substitutes. 
Both synthetic and naturally occurring products are available. Each has its specific 
composition, which determines its biological and biomechanical behavior (9-11). As such, 
each product will have its unique clinical indication(s). 
 Bone graft substitute materials provide an osteoconductive matrix, but do not contain 
osteogenic cells or osteoinductive growth factors. Sufficient porosity, especially the presence 
of interconnected pores determine the ability of bone graft materials to foster ingrowth and 
osteointegration. Pore sizes of at least 100µm are sufficient for osteoid formation and osseous 
ingrowth (12). The presence of interconnecting pores may be more critical for osseous 
ingrowth than the pore size per se (13,14). Most bone graft substitute materials used for 
treating osteoporotic fractures contain calcium sulfate or calcium phosphate. 
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Calcium sulfate is a self-setting, biologically inert, moldable, and osteoinductive 
material that provides a scaffold for osteoblasts. It rapidly dissolves (without cellular 
influence) in 6- 8 weeks. This may be advantageous in some cases, but if it dissolves too 
quickly, the augmenting effect may be lost too early, causing implant loosening. 
 Calcium phosphate materials include synthetic tricalcium phosphate, beta tricalcium 
phosphate, and coralline hydroxyapatite. The osteoconductive matrix allows osteogenic cells 
to create new bone under the influence of host osteoinductive factors. Calcium phosphate 
materials degrade at a slower rate than calcium sulfate materials, with hydroxyapatite being 
relatively inert. Calcium phosphate materials are available as block, granules, or cement. 
Blocks and granules are highly porous. They provide less initial biomechanical strength, but 
strength will increase upon ingrowth of new bone. Calcium phosphate cement is injected as a 
paste and hardens in vivo. They can be injected or molded into small bone defects and provide 
structural support with low porosity but good initial compressive strength. 
 
Use of bone graft substitutes for treatment of osteoporotic fractures 
Calcium sulfate and calcium phosphate cement have clear benefits when used for screw 
augmentation, as described in detail elsewhere (15). Clinical applications described include 
osteoporotic fractures of the proximal humerus, distal radius, vertebra, hip, and tibia plateau. 
Both calcium sulphate and phosphate cements show promising results in the treatment 
of proximal humeral fractures. Minimally invasive plate fixation (internal locking system 
(PHILOS) augmented with calcium sulfate cement (MIIG X3; Wright Medical Technology, 
Arlington, TN, USA) resulted in fewer complications, less reduction loss, and better joint 
function than plating alone (16). MIIG 115 also resulted in fewer failed reductions when 
injected in the medial metaphyseal junction (17). Reduction failed in 7.1% (1 of 14) grafted 
patients versus 13.3% (4 of 30) non-grafted patients. Functional outcome was good in both 
groups. Unfortunately, treatment allocation was not randomized. Augmentation of severely 
impacted valgus fractures with Norian, an injectable hydroxyapatite cement, resulted in good 
functional outcome (18). Augmentation was used after open reduction with screws or buttress 
plate fixation. All fractures united within the first year, and no patient showed loss of 
reductions or osteonecrosis of the humeral head. 
 Clinical benefit of bone graft substitute material use in osteoporotic distal humerus 
fractures is undecided, as studies show contradicting results. A biomechanical study showed 
that cement augmentation increased the biomechanical properties in volar plating. This 
included significant increase in cycles and load to failure, and construct stiffness at loads 
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>325 N as well as less fracture gap movement and screw cutting distance at the holes of the 
ulnar column (19). Augmentation with calcium phosphate cement also maintained fixation of 
unstable distal radius fractures (20). Garcés-Zarzalejo et al., on the other hand, stated that 
bone grafts and bone graft substitutes are not mandatory for the treatment of unstable distal 
radius fractures with locking compression plates (21). All 60 fractures in their study (treated 
without graft), healed uneventfully with no significant loss of reduction. A randomized study 
also showed that augmentation of metaphyseal defects with calcium phosphate bone cement 
after volar locking plate fixation offered no benefit over plate fixation alone (22).  
 Two studies showed increased screw hold in spine after augmentation (23,24). Bone 
graft substitutes for the treatment of osteoporotic vertebral fractures have been used for 
kyphoplasty and vertebroplasty. Although pain and the disability scores decreased after 
balloon kyphoplasty with injectable calcium phosphate cement (Callos), the augmentation 
properties also decreased within six months, including progression of vertebral height loss and 
increase in kyphotic angle (25). Epidural leakage of the paste into the spinal canal was 
observed in 48.4% (15 of 26) cases. Vertebroplasty using calcium phosphate cement resulted 
in immediate pain relief and prevented the vertebral body from late collapse and 
pseudoarthrosis (26). All 86 patients (99 vertebroplasties) had complete bone union within six 
months after surgery. Vertebroplasty using bisphosphonate-loaded calcium phosphate cement 
gave good results in sheep (27). Pedicle screw fixation combined with transpedicular bone 
grafting with demineralized bone matrix (OsteoSet, Wright Medical Technology, TN, USA) 
restored and maintained vertebral height successfully, and patients reported less pain at three 
months follow-up than pre-surgery (28). 
Two studies reported that cement augmentation can increase the rotational stability and 
screw pull-out force in osteoporotic femoral heads (29,30). Augmentation with calcium 
phosphate cement enhanced the fixation stability of femoral neck and trochanteric fractures 
(31). A meta-analysis, however, found no convincing evidence for the use of any 
orthobiologic bone cement in the augmentation of fractures of the hip (32). 
 Current evidence does not unequivocally support the need to use bone graft substitutes 
in the treatment of osteoporotic tibia plateau fractures. A meta-analysis showed that for tibia 
plateau augmentation, hydroxyapatite granules, tricalcium phosphate, demineralized bone 
matrix, allografts, and autografts all resulted in uneventful healing in >90% of cases (33). The 
rapid degradation of calcium sulfate may be a disadvantage, as 11% of cases treated with 
calcium sulfate showed subsidence (34). Injectable calcium phosphate cements allow to 
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support a reduced joint surface using a noninvasive procedure. Cement extrusion into a joint 
cavity should be prevented as these cements will not dissolve (35). 
 
Preclinical studies of the role of BMPs in osteoporosis and in osteoporotic fractures 
After the key discovery of the osteoinductive potential of BMPs to form ectopic bone reported 
by M. Urist in 1965 (8), more than 40 different BMPs have been described in the meantime. 
M. Urist himself called osteoporosis a “bone-morphogenetic auto-immune disorder” (36) and 
certain important interactions between BMPs in the pathomechanism of osteoporosis could be 
identified. Genetic polypmorphisms in BMP-2 were found to be responsible for familial 
osteoporosis [37,38]. The link between BMP-2 and osteoporosis is mainly the role of BMP-2 
in the achievement of peak bone mass rather than osteolytic activity during bone loss. Both 
decreased anabolic activity and reduced gene expression of BMP-2 have been reported in 
aged rats and reduced expression of BMP-2 was confirmed in mesenchmyal stem cells 
obtained from confirmed in ovariectomized rats [39,40]. Pountos et al. [41] could show a 
positive effect of BMP-2 and BMP-7 on the osteogenic differentiation of mesenchymal stem 
cells obtained from patients with lower extremity fractures underscoring the hypothesis to 
stimulate fracture healing in these patients by application of BMPs.   
Several studies were carried out to look at the therapeutical effect of BMPs to reverse bone 
loss in osteoporosis. Phillips et al. (2006) [42] looked at the effects of locally applied BMP-7 
with different carriers into defects of ovine vertebrae bodies. BMP-7 showed a positive trend 
in improving mechanical strength and histomorphometric parameters of osteopenic vertebra 
without statistical significance, despite the absence of consistent change in BMD. Turgemann 
et al. (2002) [43] applied exogenous BMP-2 intraperitoneal into mice with type I and type II 
osteoporosis and reported an increase of trabecular bone strength combined with an increase 
in the number of adult mesenchymal stem cells, increase of their osteogenic activity and 
proliferation as well as a decrease in apoptosis. Similar results were published for the i.v. 
application of BMP-6 applied in aged OVX rats [44]. Significantly increased bone volume 
and mechanical characteristics of both the trabecular and cortical bone, the osteoblast surface, 
serum osteocalcin and osteoprotegerin levels, and decreased the osteoclast surface, serum C-
telopeptide, and interleukin-6 were found. Bone mineral density maintained gains for another 
12 weeks after discontinuation of BMP-6 therapy.  
The preclinical literature on the effects of BMPs on osteoporotic fracture healing is poor. One 
animal study evaluated the effects of BMP-2 in a segmental tibia defect of ovariectomized vs. 
sham-operated rats. The BMP-2 treated animal exhibited higher biomechanical failure loads 
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and histology revealed a higher fracture healing score, including callus formation, bone union, 
marrow changes and cortex remodeling compared to the sham group after 8 weeks [45].  
 
Clinical evidence for the use of bone morphogenetic proteins 
Only BMP-2 and BMP-7 have been licensed for the clinical use in patients. Open tibia 
fractures and lumbar spinal interbody fusion are official indications for BMP-2 (InductOs®, 
Medtronic, Tolochenaz, Switzerland; Infuse®, Memphis, USA) and BMP-7 is licensed for 
tibial non-unions (Osigraft®, Olympus Biotech; in the meantime withdrawn from the market). 
There are statements in the Summary Product Characteristics (SPC) both of InductOs® and of 
Osigraft® stating that the “The safety and efficacy of InductOs have not been demonstrated in 
patients with metabolic bone diseases“ and “Osigraft must not be used in patients that have a 
non-union resulting from pathological fractures, metabolic bone disease (or tumors)”. This 
limits their official use in osteoporotic fracture patients if osteoporotic fractures are defined as 
pathological fractures. This is mainly due to the lacking data of the use of BMPs in 
osteoporotic patients and not due to documented adverse effects in this entity. Despite the 
theoretical benefits for improvement of fracture healing in osteoporosis, there are no 
published clinical trials, case series or case studies of BMP-2, BMP-7 or other BMPs in 
patients with osteoporotic patients. Therefore, it must be stated that there is complete absence 
of clinical evidence for BMP application in patients with osteoporotic fractures.  
 
CONCLUSION 
Given the generally compromised outcome in osteoporotic fractures and limited alternatives 
for enhancement of fracture healing, it should be assumed that bone graft substitute materials 
BMPs have been extensively studied for this entity. Therefore, it is more than disappointing 
that there is only very limited clinical data available on this indication that do not allow for an 
evidence-based algorithm. With a growing elderly population and limited treatment 
alternatives, the tremendous challenge of treating patients with osteoporotic fractures will 
become increasingly important and both bone graft materials and BMPs are still a viable 
option. Researchers and clinicians should grasp the opportunity to contribute towards this 
important topic and seriously evaluate the potential benefits and harms of these materials in 
osteoporotic fractures.  
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